TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05831306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet A
Description: Modified Diet A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet B
Description: Modified Diet B
Study: NCT06107855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Press Resistance Training Machine
Description: Participants used said unilateral leg press at 60% one-repetition max for either 3 sets x 5 reps, or 5 sets x 5 reps, at either maximal- or controlled-tempo-intent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Press Resistance Training Machine
Description: Participants used said unilateral leg press at 60% one-repetition max for either 3 sets x 5 reps, or 5 sets x 5 reps, at either maximal- or controlled-tempo-intent.
Study: NCT06357520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsule will be administered orally.
Study: NCT06777303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcurmin loaded on chitosan nano-particles
Description: the formulation of curcumin and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid loaded on chitosan nano-particles
Description: the formulation of hyaluronic acid and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planning
Description: the -ve control group in the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chitosan nano-particles
Description: the +ve control group in the study
Study: NCT06783283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial Alternating Current Stimulation (tACS) is a non-invasive electrical stimulation that will be used to stimulate the dorsolateral prefrontal cortex (dlPFC) and temporal cortices and in turn enhance Theta-Gamma Coupling (TGC) and working memory in Mild Cognitive Impairment (MCI). Each participant will receive daily stimulation for 10 days. To deliver the tACS, multiple electrodes embedded in a cap placed on the participant's head. Sham-tACS will follow the same procedure.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS
Description: During sham-tACS, the device will ramp up to the desired intensity over 30 seconds, and then will immediately ramp down, and the stimulation will be shut off, until the end of the session. At the end of the session, the device will again ramp up for 30 seconds and then ramp down. Sham-tACS will also target dlPFC and temporal cortices (similar to active). Each participant will receive daily sham-tACS for 10 days. To deliver the sham-tACS, multiple electrodes will be embedded in a cap placed on the participant's head.
Study: NCT06785961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration of traumatic tooth
Description: Revascularization is a new treatment method for immature necrotic , pulp revascularization allows also the stimulation of the apical development and the root maturation of immature teeth ( growth and thickening of dentinal walls ).
Study: NCT05465590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB1707
Description: MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism.
Study: NCT04656184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA
Description: The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
Study: NCT01351168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem first dose
Description: Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem second dose
Description: Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
Study: NCT04656184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
Study: NCT05867966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeduc/self-care/self-hypnosis group
Description: See arm description.
Study: NCT05621707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy combined with PD-1 inhibitors
Description: Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
Study: NCT05084339

Intervention type: DIAGNOSTIC_TEST
Intervention: CGM
Description: blinded CGM used at 4 different time points in pregnancy

Intervention type: DIAGNOSTIC_TEST
Intervention: CGM
Description: blinded CGM used at 4 different time points in pregnancy
Study: NCT04966975

Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
Study: NCT05886907

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal toric contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal toric contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A multifocal toric contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A multifocal toric contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution
Study: NCT05307003

Intervention type: DRUG
Intervention: Trazodone
Description: Medication used to treat ICU delirium

Intervention type: DRUG
Intervention: Quetiapine
Description: Medication used to treat ICU delirium
Study: NCT06283433

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finger Prick
Description: Blood sample obtained via drop of capillary blood by finger prick onto filter paper

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Venipuncture
Description: Blood sample obtained trough venipuncture
Study: NCT05168618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study: NCT06179043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrient warning labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* Labels that read high in sugars and high in calories~* A label that reads high in sugars

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-only health warning labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic health warning labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay and contains graphics illustrating obesity, type 2 diabetes, and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay and contains graphics illustrating type 2 diabetes and tooth decay

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A neutral bar code label~* A neutral quick response (QR) code label (not scannable)
Study: NCT04830553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-based couple therapy.
Description: Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks.
Study: NCT05418127

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Traditionally-fermented coconut milk kefir

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution of Calcium Carbonate and coconut extract
Study: NCT06297434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: J2H-1702
Description: Orally, once daily before meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: J2H-1702
Description: Orally, once daily before meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: J2H-1702
Description: Orally, once daily before meals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, once daily before meals
Study: NCT05304455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole 25Mg Tab
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Low Molecular Weight Heparin
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Study: NCT05685225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone-Acetaminophen
Description: Combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen alone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05759962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQT-1213
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQT-1213
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQT-1213
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT05761457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryopreserved autologous platelet transfusion
Description: Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20\*10E9/L or severe bleeding occurred.
Study: NCT01272505

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: converntional SILC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scalpel Single incision laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Harmonic scalpel Single incision laparoscopic cholecystectomy
Study: NCT02968459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical cord MSCs
Description: Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
Study: NCT05972642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU-treatment
Description: The investigator will sedate the subject and perform the HIFU procedure with the investigational medical device according to the pre-established procedure plan (see Table 11 for procedure plan) (procedure may take up to 2 hours). During the procedure, the investigator may modify the pre-established procedure plan by checking in with the subject occasionally to assess the presence of heat and pain at the site of the investigational device application.
Study: NCT05163938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REThink Therapeutic Game
Description: Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)
Study: NCT06102447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netopitam Palonosetron capsules and dexamethasone
Description: On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.
Study: NCT05163938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment As Usual: In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
Study: NCT05326438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIRCLE mHealth app
Description: For the intervention, participants will be given access to an mHealth sobriety app that has been modified for Alaska Native/American Indian people. The app allows people to track their sobriety, learn new recovery skills, track treatment plans, set reminders, journal about their recovery, and discover helpful videos and testimonials through an extensive resource library that includes culturally meaningful content, graphics, music, videos, recovery tools, and testimonials. Users can also participate in an interactive peer platform and/or participate in group chats to engage participants in facilitated discussions about sobriety, lifestyle changes, cultural content, and Community Reinforcement Approach skill-building.
Study: NCT05446220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Dietary advise and/or advise on physical activity monitored by pedometer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Dietary advise and/or advise on physical activity monitored by pedometer
Study: NCT04854057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAM - Intermittent Room Air - room air mixture
Description: Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAM - Intermittent Room Air - room air mixture
Description: Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice
Description: Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice
Description: Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.
Study: NCT05759065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Brief Behavioral Treatment for Insomnia
Description: Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-Cognitive-Behavioral Therapy for Insomnia
Description: Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.
Study: NCT05114564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (comfilcon A lens)
Description: 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (comfilcon A lens)
Description: 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lehfilcon A lens)
Description: 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lehfilcon A lens)
Description: 1 month
Study: NCT04611139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-2577
Description: Daily oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg Q3W by IV infusion
Study: NCT05740813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262 Dose 1
Description: ABBV-CLS-7262 is administered orally once per day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262 Dose 2
Description: ABBV-CLS-7262 is administered orally once per day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo is administered orally once per day for 24 weeks.